Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for mantle cell lymphoma and was generally well tolerated, a PrECOG early-phase trial shows
The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational